In this week's EuroBiotech Report, after years of relying heavily on Neil Woodford's checkbook, early-stage British and European biotechs could soon have another big-name investor to tap for cash: Jim Mellon--a man worth around £800 million ($1.2...
Phase II data from Genmab have ratcheted up expectations for a fast-track approval of its Johnson & Johnson-partnered treatment for double refractory multiple myeloma. Analysts see the data as strong enough to bring the CD38 monoclonal antibody to...
BASEL (dpa-AFX) - Genmab :Ofatumumab collaboration contract to be
transferred from GSK to Novartis
Denmark-based biotechnology company Genmab A/S (GNMSF.PK) said that it has
entered into an agreement with GlaxoSmithKline (GSK, GSK.L) and Novartis...
WASHINGTON (dpa-AFX) - Seattle Genetics Inc (SGEN) and Genmab A/S (GNMSF.PK)
on Wednesday entered into an additional antibody-drug conjugate collaboration.
Under the new agreement, Genmab will pay an upfront fee of $11 million for
Genmab A/S (OTC:GNMSF)
Q2 2014 Earnings Conference Call
August 13, 2014 12:00 PM ET
Jan G. J. van de Winkel – President and Chief Executive Officer
David A. Eatwell – Executive Vice President & Chief Financial...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.